ReviewLife (Basel, Switzerland)2023
Pramipexole Augmentation for Treatment-Resistant Unipolar and Bipolar Depression in the Real World: A Systematic Review and Meta-Analysis.
Review in Life (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 26 citations in OpenAlex.
- Efficacy and target engagement of dopamine agonist pramipexole for anhedonic depression: a randomized placebo-controlled trial.Nature medicine · 2026Trial
- Comparative pharmacovigilance of Levodopa and Pramipexole: a disproportionality analysis of the FAERS database.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026Article
- Molecular and neural circuit mechanisms of parvalbumin (PV) neurons in depression: Insights and advances.iScience · 2026Review
- Imbalance in excitation and inhibition in sgACC is associated with depression in dementia with Lewy bodies.Translational psychiatry · 2026Article
- Do we need drugs for psychiatric symptoms specifically for Parkinson's disease?Journal of Parkinson's disease · 2026Review
- Pramipexole treatment and substance use disorder risk in unipolar and bipolar depression: a Swedish nationwide register study.Frontiers in psychiatry · 2026Article
- Clinical practice guidelines for the management of bipolar disorder: 2025 update.Indian journal of psychiatry · 2026Article
- Molecular Mechanisms of Depression: The Interplay Between Genes and Receptors.International journal of molecular sciences · 2025Review
- Bromocriptine, Selegiline and Amantadine in the Treatment of Depression-A Systematic Review.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Defining Treatment-Resistant Bipolar Depression: Recommendations From the ISBD Task Force.Bipolar disorders · 2025Review
- Comprehensive Review on Association of Bipolar Disorder and Substance Abuse: Dual Diagnosis and Treatment Approaches.Cureus · 2025Review
- Dopaminergic changes in the subgenual cingulate cortex in dementia with lewy bodies associates with presence of depression.Translational psychiatry · 2025Article
- Comparative safety signals of dopamine agonists: psychiatric and cardiovascular risks derived from FDA adverse event reporting system (FAERS) data.BMC pharmacology & toxicology · 2025Article
- Trends in research on novel antidepressant treatments.Frontiers in pharmacology · 2025Review
- Are There Connections between the Neuroendocrine and Dopamine Systems in Bipolar Disorder?Neuroendocrinology · 2025Review
- Treatment-resistant depression: molecular mechanisms and management.Molecular biomedicine · 2024Review
- Comparative Short- and Long-Term Effectiveness and Safety of Pramipexole and Aripiprazole Augmentation in Treatment-Resistant Unipolar Depression: An Observational Study.Biomedicines · 2024Article
- The association between vitamin C and depressive risk based on the National Health and Nutrition Examination Survey of 2017-2018 and Mendelian randomization study.American journal of translational research · 2024Article
- Add-on pramipexole for anhedonic depression: study protocol for a randomised controlled trial and open-label follow-up in Lund, Sweden.BMJ open · 2023Article
- Bipolar Disorder Among Older Adults: Newer Evidence to Guide Clinical Practice.Focus (American Psychiatric Publishing) · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundPramipexole is a dopamine full agonist approved for the treatment of Parkinson's disease and restless legs syndrome. Its high affinity for the D3 receptor and neuroprotective, antioxidant, and anti-inflammatory activity provides a rationale for the treatment of depression. In this paper, we review studies on the effectiveness and safety of antidepressant pramipexole augmentation in treatment-resistant depression.
methodsThis comprehensive systematic review and meta-analysis of observational studies on pramipexole-antidepressant augmentation included patients with resistant unipolar and bipolar depression. The primary outcome measure was the treatment response, measured at the study endpoint.
resultsWe identified 8 studies including 281 patients overall, 57% women and 39.5% with bipolar disorder and 60.5% with major depressive disorder. The mean follow-up duration was 27.3 weeks (range 8-69). The pooled estimate of treatment response was 62.5%, without significant differences between unipolar and bipolar depression. Safety was good, with nausea and somnolence the most frequent side effects.
conclusionsThe findings of this systematic review, needing further confirmation, show that off-label use of pramipexole as augmentation of antidepressant treatment could be a useful and safe strategy for unipolar and bipolar treatment-resistant depression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.